Replies to post #242071 on Biotech Values

[DewDiligence]

PRDS +7% today—could be related to Shionogi mishap.

[vinmantoo]

(ENTA)—Shionogi antiviral is teratogenic—>out_of_contention_for_best-in-class_COVID_drug:

Their drug is a protease inhibitor as is Paxlovid. The latter shows a decrease in fetal size so his may be a general class effect. The problem is likely off target effects on other proteases, Caspases come to mind. ENTA just released data showing it has very high specificity for the Covid protease (see Dew's message below) so it might not be as problematic for ENTA but time will tell.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168493419)

[DewDiligence]

Shionogi PR re COVID antiviral fails to mention teratogenicity!

https://www.businesswire.com/news/home/20220423005001/en

Shionogi is evidently acting like MRK did with Molnupiravir—i.e. pretending that a safety issue does not exist. In MRK’s case, the result was a product with essentially no demand because the FDA EUA restricts usage to patients “for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate” (#msg-167236732).

[DewDiligence]

(ENTA)—Shionogi’s COVID antiviral hits another setback:

https://www.bloomberg.com/news/articles/2022-07-20/shionogi-covid-pill-fails-to-win-japan-s-panel-backing

Shionogi & Co.’s experimental Covid-19 treatment Xocova failed to win the backing of health experts in Japan who said there wasn’t enough data to show the medicine’s efficacy.